Realheart has been granted two more US patents

Press release 2 May, 2022

Realheart is developing the world's first artificial four-chamber heart. The company has now been granted a new US patent that protects the entire principle behind it through 2037. In addition, the company has obtained similar protection for its sternal prosthesis, a separate product designed to facilitate chest surgery.

''This is extremely valuable as it provides a strong two-layer protection for our artificial heart in one of the world's most important markets and further strengthens our overall patent portfolio'' said Realheart CEO Ina Laura Perkins.

In December, Realheart was granted a US patent protecting the unique pumping principle used in Realheart's artificial heart, which can also be used in other products. Now, in addition to that, it has received a new patent, number US11202902B2, which protects the Realheart TAH as a whole. This patent has already been granted in Europe, Japan and Australia.

The second patent, number US11191578B2, protects Realheart's sternal prosthesis, a zipper-like innovation that allows the chest to be reopened and closed if necessary after surgery. It is also intended to relieve pain. This patent too has already been approved in Europe.

Both new patents are valid until 2037.

For more information please contact:

Ina Laura Perkins, CEO

Phone: +46(0)70 406 49 21 

E-mail: inalaura.perkins@realheart.se

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Phone: +46 11 32 30 732, email: ca@skmg.se

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart TAH has a unique, patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation.